Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval PharmaphorumTakeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.NeuroscienceRead full story pharminent August 6, 2026 (Last updated: August 8, 2026) Pharmaphorum Takeda’s orexin agonist Orzeyful is the first drug approved in the US that can treat the “full range” of narcolepsy type 1 symptoms, says the FDA. Neuroscience Read full story Post navigation Previous: Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 SurgeNext: FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu Vaccine Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026